肝硬化患者出院后同一医院与不同医院再入院比较
该研究利用2013年美国全国再入院数据库,分析肝硬化患者再入院特征。结果显示,肝硬化再入院中67%为同一医院再入院,33%为不同医院再入院(P<0.001),30天再入院率为29.1%。不同医院再入院未增加30天再入院风险(校正风险比1.044,95%CI 0.975-1.118)及住院死亡风险,但与更高的住院费用和住院时长相关。
要点
- 肝硬化再入院中67%为同一医院再入院,33%为不同医院再入院(P<0.001)。
- 不同医院再入院未增加30天再入院风险及住院死亡风险。
- 不同医院再入院与更高的住院费用和住院时长相关。
核心结论
- 大多数肝硬化再入院为同一医院再入院,不同医院再入院不增加30天再入院及住院死亡风险,但与更高的住院费用相关。
研究设计与样本
- 使用美国全国再入院数据库,识别2013年肝硬化住院病例,采用回归分析确定不同医院再入院的预测因素,并进行时间-事件分析评估对后续再入院及全因住院死亡的影响。
主要发现
- 2013年共有109,039例肝硬化再入院,其中67%为同一医院再入院,33%为不同医院再入院(P<0.001)。
- 2%的再入院患者在≥4家不同医院接受治疗。
- 30天再入院率为29.1%。
- 不同医院再入院的预测因素包括医疗补助支付者(校正比值比1.07,95%CI 1.01-1.14)、年龄(比值比0.98,95%CI 0.978-0.982)、择期入院(比值比1.09,95%CI 1.01-1.17)、肝性脑病(比值比1.20,95%CI 1.16-1.25)、肝肾综合征(比值比1.09,95%CI 1.03-1.16)和低社会经济地位(比值比1.15,95%CI 1.06-1.25)。
- 不同医院再入院后30天再入院风险无差异(校正风险比1.044,95%CI 0.975-1.118),30天内不同医院再入院期间住院死亡风险未增加(校正风险比1.08,95%CI 0.94-1.23)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: There is a lack of data on the impact of readmission to the same vs a different hospital following an index hospital discharge in cirrhosis patients. METHODS: We sought to describe rates and predictors of different-hospital readmissions (DHRs) among patients with cirrhosis and also determine the impact on cirrhosis outcomes including all-cause inpatient mortality and hospital costs. Using the national readmissions database, we identified cirrhosis hospitalizations in 2013. Regression analysis was used to determine the predictors of DHRs. A time-to-event analysis was performed to assess the impact on subsequent readmissions and all-cause inpatient mortality. RESULTS: In 2013, there were 109,039 cirrhosis readmissions with 67% of these being same-hospital readmissions and 33% being DHRs (P < 0.001). Two percent of readmitted patients were treated at ≥4 different hospitals. The 30-day readmission rate was 29.1%. Predictors of DHR included Medicaid payer (adjusted odds ratio [OR] 1.07, 95% confidence interval [95% CI] 1.01-1.14), age (OR 0.98, 95% CI 0.978-0.982), elective admission (OR 1.09, 95% CI 1.01-1.17), hepatic encephalopathy (OR 1.20, 95% CI 1.16-1.25), hepatorenal syndrome (OR 1.09, 95% CI 1.03-1.16), and low socioeconomic status (OR 1.15, 95% CI 1.06-1.25). No difference was observed in 30-day readmission risk following a DHR (adjusted hazard ratio 1.044, 95% CI 0.975-1.118). In addition, there was no increased risk of inpatient death observed during a DHR within 30 days (adjusted hazard ratio 1.08, 95% CI 0.94-1.23). However, patients with DHR had significantly higher hospital costs and length of stay. CONCLUSIONS: Majority of cirrhosis readmissions are same-hospital readmissions. Different-hospital readmissions do not increase the risk of 30-day readmissions and inpatient mortality but are associated with higher hospital costs.
引用
- Okafor PN, Nnadi AK, Okoli O, et al. Same- vs Different-Hospital Readmissions in Patients With Cirrhosis After Hospital Discharge. Am J Gastroenterol. 2019. PMID: 30676364. doi:10.14309/ajg.0000000000000050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。